SHPHF Stock Chart & Stats
$0.12
>-$0.01(-7.48%)
At close: 4:00 PM EDT
$0.12
>-$0.01(-7.48%)
Day’s Range― - ―
52-Week Range$0.10 - $0.21
Previous CloseN/A
Volume2.00K
Average Volume (3M)0.00
Market Cap
$880.41M
Enterprise Value$6.90K
Total Cash (Recent Filing)$3.72B
Total Debt (Recent Filing)$969.22M
Price to Earnings (P/E)19.1
Beta0.45
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.16%
Share Statistics
EPS (TTM)0.03
Shares Outstanding9,329,999,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)1.72
Price to Sales (P/S)3.85
P/FCF Ratio-46.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)$438.56M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe 2025 revenue rebound and return to profitability indicate renewed demand across the company’s pharmaceutical portfolio. If sustained, stronger sales can improve operating leverage, support investment in commercialization and R&D, and reinforce its position in China’s hospital and medical channels over the coming quarters.
High Gross MarginsPersistently high gross margins provide a meaningful economic base for Sihuan’s branded generics and prescription medicines. This margin profile can support marketing, product development and portfolio management while offering some protection for earnings generation, provided pricing and product demand remain stable.
Manageable LeverageDeclining debt relative to equity indicates reduced balance-sheet pressure and gives the company greater flexibility through business volatility. A sizable equity cushion can help Sihuan fund operations and pursue its pharmaceutical strategy without relying as heavily on additional borrowing.
Bears Say
Weak Cash ConversionNegative operating and free cash flow despite positive reported net income signals weak cash conversion and lowers the quality of the earnings rebound. If this persists, internally generated funding for R&D, commercialization and other business needs could remain constrained, increasing financial-flexibility risk.
Earnings VolatilityThe sharp swings from substantial losses to a 2025 recovery make the company’s earnings base less predictable than its strong gross margins suggest. Such volatility complicates planning, reduces confidence in recurring profitability, and leaves future performance sensitive to changes in product and market conditions.
Low Shareholder ReturnsA low latest-year ROE, following negative returns in earlier periods, shows that the company’s sizable equity base is not yet producing consistently strong shareholder returns. This limits the effectiveness of its balance-sheet strength and indicates that profitability improvement still needs to become more durable.
Sihuan Pharmaceutical Holdings Group News
SHPHF FAQ
What was Sihuan Pharmaceutical Holdings Group Ltd.’s price range in the past 12 months?
Sihuan Pharmaceutical Holdings Group Ltd. lowest stock price was $0.10 and its highest was $0.21 in the past 12 months.
What is Sihuan Pharmaceutical Holdings Group Ltd.’s market cap?
Sihuan Pharmaceutical Holdings Group Ltd.’s market cap is $880.41M.
When is Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date?
Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 188 days.
How were Sihuan Pharmaceutical Holdings Group Ltd.’s earnings last quarter?
Sihuan Pharmaceutical Holdings Group Ltd. released its earnings results on Aug 26, 2026. The company reported $0.004 earnings per share for the quarter.
Is Sihuan Pharmaceutical Holdings Group Ltd. overvalued?
According to Wall Street analysts Sihuan Pharmaceutical Holdings Group Ltd.’s price is currently Overvalued.
Does Sihuan Pharmaceutical Holdings Group Ltd. pay dividends?
Sihuan Pharmaceutical Holdings Group Ltd. pays a Annually dividend of $0.001 which represents an annual dividend yield of 1.16%. See more information on Sihuan Pharmaceutical Holdings Group Ltd. dividends here
What is Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate?
Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sihuan Pharmaceutical Holdings Group Ltd. have?
Sihuan Pharmaceutical Holdings Group Ltd. has 9,329,999,000 shares outstanding.
What happened to Sihuan Pharmaceutical Holdings Group Ltd.’s price movement after its last earnings report?
Sihuan Pharmaceutical Holdings Group Ltd. reported an EPS of $0.004 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sihuan Pharmaceutical Holdings Group Ltd.?
Currently, no hedge funds are holding shares in SHPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sihuan Pharmaceutical Holdings Group Ltd.
Sihuan Pharmaceutical Holdings Group Ltd. is an investment holding company that engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products. Its portfolio includes products for the cardio-cerebral vascular system, as well as segments for innovative medicine, generic medicine, and medical aesthetics which includes injectables, energy-based devices, and skincare solutions. The company operates primarily in the People's Republic of China, with some international presence.
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Ownership Overview
― Insiders
2.05% Mutual Funds
<0.01% Other Institutional Investors
95.87% Public Companies and
Individual Investors